Comparing two drug combos for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your daily activity level is good (you can care for yourself and do light activities).
- Your doctor believes you are likely to live at least 12 more weeks.
- Your nasopharyngeal cancer has returned after treatment or spread to other parts of the body.
- It has been at least 4 weeks since your last chemotherapy treatment.
- You have at least one tumor that can be measured on a scan (and it hasn't been previously treated with radiation).
- Your major organs (like liver, kidneys, and bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of MRG003 (a targeted drug) plus immunotherapy for people with nasopharyngeal cancer that has spread or come back and cannot be removed with surgery or radiation. The goal is to see if this combination helps control the cancer.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.